These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 28787710)
21. Efficacy of 4 weeks topical bifonazole treatment for onychomycosis after nail ablation with 40% urea: a double-blind, randomized, placebo-controlled multicenter study. Tietz HJ; Hay R; Querner S; Delcker A; Kurka P; Merk HF Mycoses; 2013 Jul; 56(4):414-21. PubMed ID: 23586591 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of efficacy and tolerability of four weeks bifonazole treatment after nail ablation with 40% urea in mild to moderate distal subungual onychomycosis. Piraccini BM; Bruni F; Alessandrini A; Starace M G Ital Dermatol Venereol; 2016 Feb; 151(1):32-6. PubMed ID: 26472342 [TBL] [Abstract][Full Text] [Related]
23. Coexistence of onychomycosis and nail psoriasis and its correlation with systemic treatment. Grynszpan R; Barreiros G; do Nascimento Paixão M; Frasnelli Fernandes M; Aguinaga F; Camargo C; Ramos-E-Silva M; Carneiro S Mycoses; 2021 Sep; 64(9):1092-1097. PubMed ID: 34061419 [TBL] [Abstract][Full Text] [Related]
24. Concealing Meets Healing in the Treatment of Toenail Onychomycosis: A Review of Concurrent Nail Polish Use with Topical Efinaconazole 10% Solution. Pandit B; Elewski B; Vlahovic TC J Clin Aesthet Dermatol; 2024 Sep; 17(9):38-42. PubMed ID: 39263266 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of the Appearance of Nail Polish Following Daily Treatment of Ex Vivo Human Fingernails With Topical Solutions of Tavaborole or Efinaconazole. Vlahovic TC; Coronado D; Chanda S; Merchant T; Zane LT J Drugs Dermatol; 2016 Jan; 15(1):89-94. PubMed ID: 26741386 [TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis. Paul C; Coustou D; Lahfa M; Bulai-Livideanu C; Doss N; Mokthar I; Turki H; Nouira R; Fazaa B; Ben Osman A; Zourabichvili O; Cazeau C; Coubetergues H; Picot S; Bienvenu AL; Voisard JJ Dermatology; 2013; 227(2):157-64. PubMed ID: 24051622 [TBL] [Abstract][Full Text] [Related]
27. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails. Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707 [TBL] [Abstract][Full Text] [Related]
28. Coexistence of onychomycosis in psoriatic nails: a descriptive study. Natarajan V; Nath AK; Thappa DM; Singh R; Verma SK Indian J Dermatol Venereol Leprol; 2010; 76(6):723. PubMed ID: 21079333 [TBL] [Abstract][Full Text] [Related]
29. Onychomycosis in patients with nail psoriasis: a point to point discussion. Rigopoulos D; Papanagiotou V; Daniel R; Piraccini BM Mycoses; 2017 Jan; 60(1):6-10. PubMed ID: 27523738 [TBL] [Abstract][Full Text] [Related]
30. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. Gupta AK; Konnikov N; Lynde CW J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118 [TBL] [Abstract][Full Text] [Related]
31. Tips to treat the 5 most common nail disorders: brittle nails, onycholysis, paronychia, psoriasis, onychomycosis. Iorizzo M Dermatol Clin; 2015 Apr; 33(2):175-83. PubMed ID: 25828710 [TBL] [Abstract][Full Text] [Related]
32. Clinical Evaluation of a Topical Formulation for the Management of Onychomycosis. Maggioni D; Cimicata A; Praticò A; Villa R; Bianchi F; Badiale SB; Piana U; Angelinetta C J Clin Aesthet Dermatol; 2020 Jul; 13(7):53-57. PubMed ID: 32983339 [No Abstract] [Full Text] [Related]
33. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. Elewski BE; Aly R; Baldwin SL; González Soto RF; Rich P; Weisfeld M; Wiltz H; Zane LT; Pollak R J Am Acad Dermatol; 2015 Jul; 73(1):62-9. PubMed ID: 25956661 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184 [TBL] [Abstract][Full Text] [Related]
36. Onychomycosis in patients with psoriasis--a multicentre study. Zisova L; Valtchev V; Sotiriou E; Gospodinov D; Mateev G Mycoses; 2012 Mar; 55(2):143-7. PubMed ID: 21771106 [TBL] [Abstract][Full Text] [Related]
37. Improvement of psoriatic onychodystrophy by a water-soluble nail lacquer. Cantoresi F; Sorgi P; Arcese A; Bidoli A; Bruni F; Carnevale C; Calvieri S J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):832-4. PubMed ID: 19470045 [TBL] [Abstract][Full Text] [Related]
38. Rapid cosmetic improvements in nail psoriasis patients treated with K101-03. Piraccini BM; Starace M; Toft A Eur J Dermatol; 2018 Apr; 28(2):272-274. PubMed ID: 29724689 [No Abstract] [Full Text] [Related]
39. Review of the literature on the efficacy and safety of a new cosmetic topical treatment containing Pistacia lentiscus and hyaluronic acid for the treatment of nail plate damages. Starace M; Granger C; Carpanese MA; Alessandrini A; Bruni F; Piraccini BM J Cosmet Dermatol; 2022 Nov; 21(11):5514-5518. PubMed ID: 35962760 [TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. Elewski BE; Ghannoum MA; Mayser P; Gupta AK; Korting HC; Shouey RJ; Baker DR; Rich PA; Ling M; Hugot S; Damaj B; Nyirady J; Thangavelu K; Notter M; Parneix-Spake A; Sigurgeirsson B J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):287-94. PubMed ID: 22181693 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]